Introduction 1
Estrogens, especially 17β-estradiol (E2), control the proliferation and differentiation of the 2 epithelial cells of the mammary gland (Couse and Korach, 1999) . The effects of E2 are principally 3 mediated by the estrogen receptors (ERs), which regulate the expression of specific target genes after 4 binding to regulatory regions. In addition to its crucial roles in physiology, ERα is also associated with 5 human pathological processes, such as in estrogen-dependent breast cancers (Deroo and Korach, 6 2006) . Approximately 70% of diagnosed breast cancers express ERα, which mediates mitogenic 7 effects in a E2-dependent manner (Dahlman-Wright et al., 2006; Zhao et al., 2008; 2011) , and breast 8 tumors expressing ERα often appear to be more differentiated and less invasive than ERα-negative 9 cancers (Rochefort et al., 1998; Platet et al., 2004) . Furthermore, the proliferation of ERα-positive 10 cancer cells can be repressed by anti-estrogens, such as tamoxifen, which are already used in hormone 11 therapy (Wickerham et al., 2009; Kim et al., 2011) . For these reasons, ERα expression is generally 12 associated with a good prognosis. Unfortunately, over time, ERα-positive breast tumors can escape 13 from hormonal control, becoming resistant to hormone therapy, and switch from a well-differentiated 14 epithelial phenotype to a metastatic and aggressive one (Rau et al., 2005) . Hormone-resistant cells 15 frequently exhibit a loss in ERα activity or expression, while the activity of growth receptor signaling 16 increases (Barone et al., 2010; Murphy et al., 2011) . For example, the up-regulation of EGFR 17 expression occurs in some tumors and serves as an alternative survival and proliferation pathway 18 (Newby et al., 1997) . Despite numerous studies on the topic, the molecular mechanisms involved in 19 the loss of hormonal responses are still unclear.
20
Growing evidence suggests a role for the myocardin-related transcription factor MKL1 21 (megakaryoblastic leukemia 1, also termed MRTF-A, MAL, or BSAC) in cancer progression as a 22 tumor-promoting or tumor-suppressor factor, depending on the cellular context (Medjkane et al., 2009;  23 Scharenberg et al., 2010; Hu et al., 2011; Muehlich et al., 2011) . MKL1 was first described as a 24 coactivator of serum response factor (SRF) in the control of motile or contractile cell functions, 25 especially during vascular smooth muscle cell and cardiac myocyte differentiation, neuronal 26 migration, or cancer metastasis (Cen et al., 2003; Scharenberg et al., 2010) . MKL1 continuously 27 4 shuttles between the nucleus and cytoplasm via a process controlled by the cellular pool of globular actin 1 (G-actin) (Posern et al., 2002) . The nuclear import of MKL1 is regulated by RhoA activity on actin 2 dynamics. Sequestered in an inactive form by G-actin in the cytosol, MKL1 is released following the 3 polymerization of G-actin into filamentous actin (F-actin), which is induced by RhoA (Busche et al., 4 2008 , 2010 . Nuclear G-actin has also been demonstrated to facilitate the nuclear export of MKL1.
5
Although the localization and activity of MKL1 are controlled by G-actin, the two events remain 6 independent from each other (Vartiainen et al., 2007; Muehlich et al., 2008) . In epithelial-like cells, 7 the actin/MKL1 signaling pathway is notably activated by the loss of cell-cell junctions that occurs 8 during the epithelial-mesenchymal transition (EMT) (Micalizzi et al., 2010 ).
9
We have previously shown that the Rho/actin/MKL1 signaling pathway is also a main actor in 10 controlling ERα transcriptional activity (Huet et al., 2008 (Huet et al., , 2009 . In transient transfection experiments, the 11 transactivation efficiency of ERα results in part from the respective contribution exerted by its two 12 activation functions, AF1 and AF2, the activities of which are tightly regulated in a cell differentiation 13 stage-dependent manner (Mérot et al., 2004a) . Precisely, the more differentiated a cell is, the more that 
23
MKL1 is present on the promoter of all tested E2-regulated genes (Huet et al., 2009 (Briand et al., 1996) were routinely maintained in DMEM / hams F12 16 (GIBCO) supplemented with insulin, transferrin, and sodium selenite (Insulin-Transferrin-Selenium 17 100X, GIBCO), 10 -10 M E2, 0.5 µg/mL hydrocortisone (Sigma), and 5 µg/mL ovine prolactin (Sigma).
18
Flasks coated with collagen IV (BD Bioscience) were used for culturing the HMT-3522 T4-2 cells. (Fig. 1, panel A) . Changes in actin dynamics are a hallmark of EMT. Therefore, the F/G-actin 23 ratio was determined in the four cell lines by immunofluorescence staining using phalloidin and 24 DNase I, which bind specifically to F-and G-actin, respectively (Fig. 1, panel C) . A quantitative 25 assessment of the fluorescence intensity revealed a 2-fold increase in the F/G-actin ratio in the 26 9 dedifferentiated ERα-negative cell lines versus the ERα-positive cell lines. Because an increased F/G-1 actin ratio activates MKL1 (Posern et al., 2002; Busche et al., 2008) , the ERα-negative cell lines were 2 expected to have higher MKL1 activity. MKL1 was expressed in the four cell lines, as shown by 3 western blotting (Fig. 1, panel B 
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To further investigate the impact of MKL1 on hormone-dependent breast cancer cells, we 13 generated MCF-7 sub-clones using a tetracycline-inducible vector system to stably express the MKL1-14 WT, -ΔN200, or -ΔC301 forms. Deleted of the N-terminal RPEL motifs, MKL1-ΔN200, is a 15 constitutively active form, whereas MKL1-ΔC301 behaves as a dominant negative form due to the 16 deletion of the transactivation domain (Cen et al., 2003) . In addition to the first series of individual 17 MCF-7 sub-clones, two individual clones expressing mutant forms of MKL1 were selected (Clones 2 18 and 3). It should be noted that all the data obtained with these additional clones mostly confirm the 19 results obtained with the first series (clone 1) (suppl. 2). We first controlled MKL1 protein expression 20 in the different sub-clones using western blotting and immunofluorescence methods (Fig. 3, panel A, 
21
B, and suppl. 2). Proteins of interest were produced after tetracycline treatment only (suppl. 2). The 22 nuclear localization of Flagged-MKL1-WT and MKL1-ΔC301 was observed in less than 10% of the 23 cells, whereas most of the cells showed MKL1-ΔN200 localized in the nucleus (Fig. 3, panel B) . The 24 activity of the MKL1 mutants was confirmed by western blot monitoring of the expression level of 25 SRF, c-fos, or α-actin, three known targets of the actin/MKL1 signaling pathway (Fig. 3, (Fig. 3, panel C) . Regardless of the form of MKL1 (WT, MKL1-ΔN200, and 3 MKL1-ΔC301), ER was down-regulated when MKL1 was nuclear. Therefore, the nuclear localization 4 of MKL1 proteins and ERα are mutually exclusive (Fig. 3, panel B) . Quantitative real-time PCR 5 experiments demonstrated that ERα expression was also repressed at the mRNA level in MCF-6 7/MKL1-ΔN200 cells (Fig. 3, panel D) . Interestingly, MKL1-ΔN200 also exhibited down-regulated 7 GATA3, a hallmark of hormonal responsiveness. Therefore, the estrogenic responses of PR and pS2, shown to be up-regulated by E2, whereas the expression of the receptors HER1 and HER2 is repressed 19 (Normanno et al., 1993; Zhang et al., 1994; Dardes et al., 2002) . As expected, the expression of TGFα 20 and amphiregulin was induced by E2 in the MCF-7/cont, MCF-7/MKL1, and MCF-7/MKL1-ΔC301 21 cells. HER1 and HER2 expression was also repressed by E2 in these three cell lines. Surprisingly, the 22 expression of the TGFα and amphiregulin genes was strongly enhanced in a hormone-independent 23 manner in MCF-7/MKL1-ΔN200. In the same way, HB-EGF, a membrane-bound growth factor over-24 expressed in malignant cells (Miyamoto et al., 2006) , was dramatically up-regulated in these cells. In 25 parallel, the expression level of the receptor HER1 was no longer down-regulated by E2, remaining at 26 a high level in the presence of the steroid. Finally, HER2 expression was clearly down-regulated in a 27 13 hormone-independent manner in the MCF-7/MKL1-ΔN200 cells. Western blots probing the 1 MAPK/ERK and PI3K/Akt signaling pathways revealed an activation of these signaling pathways in 2 the MCF-7/MKL1-ΔN200 compared to control or MCF-7/MKL1 cells (Fig. 4, (Fig. 4, panel D) . Because the deregulation of E2-induced proliferation is often associated with resistance to 1 tamoxifen, we then assessed the impact of tamoxifen treatment on cell growth. For that purpose, the 2 four MCF-7 sub-clones were cultivated in media containing 5% FBS and treated for 48 h with 4-OHT 3 or vehicle; the cell cycle was then analyzed by flow cytometry (Fig. 5, panel A) 
15
In conclusion, our study highlights the impact of MKL1 activation on MCF-7 breast cancer 16 cell proliferation and its role in the acquisition of a hormone-independent phenotype. With regard to 17 its hormonal escape-promoting effect, the MKL1 pathway could represent an interesting target for 18 mammary tumor therapies.
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